Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Barbara Troupin, MD, MBA
NEXMED (U.S.A.), Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Diagnamics, Inc.
Encinitas, California, United States
- University of Michigan Scleroderma Program - Division of Rheumatology/dept. of Internal Medicine
Ann Arbor, Michigan, United States
- Cleveland Clinic
Cleveland, Ohio, United States
- Scleroderma Research Center - University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2014
- Primary completion
- 30 Jun 2015
- Completion
- 31 Dec 2015
- Last update posted
- 22 Mar 2016
- Registered enrollment
- 35
- Registry id
- NCT02228850
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.